单剂口服霍乱活疫苗株CVD 103-HgR在18-45岁健康成人中的安全性与免疫原性
一项3期、安慰剂对照、双盲、多中心研究将3146名18-45岁成人按8:1随机分配接种单剂1×10^9 CFU的PXVX0200(三个生产批次)或生理盐水安慰剂,评估安全性与免疫原性。第11天疫苗组血清杀弧菌抗体(SVA)血清转化率为94%,安慰剂组为4%(P < .0001),疫苗组累积SVA血清转化率达96%。PXVX0200免疫原性良好且耐受性良好,三个生产批次间免疫原性与安全性终点等效。
要点
- 第11天SVA血清转化率疫苗组94% vs 安慰剂组4%(P < .0001),疫苗组累积血清转化率96%。
- PXVX0200组SVA GMT在第11天达峰,至第181天仍显著高于安慰剂组。
- 大多数反应原性为轻度并在1-3天内缓解,头痛和腹泻在PXVX0200组报告更频繁。
核心结论
- PXVX0200具有免疫原性且耐受性良好,三个生产批次间免疫原性与安全性终点等效。
研究设计与样本
- 3期、安慰剂对照、双盲、多中心研究,18-45岁成人志愿者按8:1随机接受单剂1×10^9 CFU的PXVX0200(三个生产批次)或生理盐水安慰剂。
- 共入组3146名参与者,其中疫苗组2795名、安慰剂组351名。
- 免疫原性终点包括第1、11、29、91和181天的SVA和抗霍乱毒素(CT)抗体水平;安全性通过比较第1-8天征集性体征和症状、至第29天非征集性不良事件及至第181天严重不良事件评估。
主要发现
- 第11天SVA血清转化率疫苗组94% vs 安慰剂组4%(P < .0001)。
- 疫苗组累积SVA血清转化率为96%。
- PXVX0200组SVA GMT在第11天达峰,至第181天仍显著高于安慰剂组;PXVX0200组抗-CT抗体较基线的倍数升高在每个疫苗接种后时间点均显著大于安慰剂组。
- 大多数反应原性为轻度并在1-3天内缓解,头痛和腹泻在PXVX0200组报告更频繁;非征集性不良事件无差异,无研究相关严重不良事件。
- 三个生产批次间免疫原性与安全性终点等效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The attenuated recombinant Vibrio cholerae O1 vaccine strain CVD 103-HgR, re-developed as PXVX0200, elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera diarrhea in volunteer challenge studies. We performed a phase 3, placebo controlled, double blind, multi-center study to further assess the safety, immunogenicity, and lot-to-lot consistency of PXVX0200. Adult volunteers 18-45 years of age were randomized 8:1 to receive a single dose of 1 × 109 CFU of PXVX0200 from three production lots or saline placebo. Immunogenicity endpoints included SVA and anti-cholera toxin (CT) antibody levels on days 1, 11, 29, 91 and 181. Safety was assessed by comparing solicited signs and symptoms on days 1-8, unsolicited adverse events through day 29 and serious adverse events through day 181. A total of 3146 participants were enrolled, including 2795 vaccine and 351 placebo recipients. The SVA seroconversion rates at day 11 were 94% and 4% in the PXVX0200 and placebo recipients, respectively (P < .0001). Cumulative SVA seroconversion occurred among 96% of vaccine recipients. PXVX0200 SVA GMTs peaked on day 11 and remained significantly higher than placebo through day 181 while the fold-rise over baseline in PXVX0200 anti-CT antibody was significantly greater than placebo at every post-vaccination time point. Most reactogenicity was mild and resolved within 1-3 days with headache and diarrhea more frequently reported in PXVX0200 recipients. There were no differences in unsolicited adverse events and no study-related serious adverse events. Immunogenicity and safety endpoints were equivalent between the three production lots. PXVX0200 is immunogenic and well tolerated across multiple production lots. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov NCT02094586.
引用
- McCarty JM, Lock MD, Hunt KM, et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. Vaccine. 2018. PMID: 29317118. doi:10.1016/j.vaccine.2017.12.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。